Cargando…

Hypoxia Selectively Impairs CAR-T Cells In Vitro

Hypoxia is a major characteristic of the solid tumor microenvironment. To understand how chimeric antigen receptor-T cells (CAR-T cells) function in hypoxic conditions, we characterized CD19-specific and BCMA-specific human CAR-T cells generated in atmospheric (18% oxygen) and hypoxic (1% oxygen) cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berahovich, Robert, Liu, Xianghong, Zhou, Hua, Tsadik, Elias, Xu, Shirley, Golubovskaya, Vita, Wu, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562712/ https://www.ncbi.nlm.nih.gov/pubmed/31052261 http://dx.doi.org/10.3390/cancers11050602

Ejemplares similares

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
por: Golubovskaya, Vita, et al.
Publicado: (2023)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
por: Golubovskaya, Vita, et al.
Publicado: (2017)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers
por: Sureban, Sripathi M., et al.
Publicado: (2019)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
por: Golubovskaya, Vita, et al.
Publicado: (2016)

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth
por: Golubovskaya, Vita, et al.
Publicado: (2023)

CAR-T Cell Therapy: From the Bench to the Bedside
por: Golubovskaya, Vita
Publicado: (2017)

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”
por: Golubovskaya, Vita
Publicado: (2023)

Editorial on Special Issue “Immunotherapy, Tumor Microenvironment and Survival Signaling”
por: Golubovskaya, Vita
Publicado: (2021)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
por: Liao, Qibin, et al.
Publicado: (2020)

Cancer Immunotherapy: Where Next?
por: Bodmer, Walter, et al.
Publicado: (2023)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers
por: Sureban, Sripathi M., et al.
Publicado: (2022)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

Editorial On “Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy”
por: Golubovskaya, Vita, et al.
Publicado: (2020)

CAR links hypoxia signaling to improved survival after myocardial infarction
por: Freiberg, Fabian, et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
por: Kosti, Paris, et al.
Publicado: (2021)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?
por: Prinzing, Brooke, et al.
Publicado: (2021)

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
por: Wang, Xueyin, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

The direct effect of Focal Adhesion Kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis
por: Golubovskaya, Vita M, et al.
Publicado: (2009)

Focal adhesion kinase protein regulates Wnt3a gene expression to control cell fate specification in the developing neural plate
por: Fonar, Yuri, et al.
Publicado: (2011)

FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics
por: O'Brien, Shalana, et al.
Publicado: (2014)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex
por: Golubovskaya, Vita M., et al.
Publicado: (2014)

Avidity‐Based Selection of Tissue‐Specific CAR‐T Cells from a Combinatorial Cellular Library of CARs
por: Ma, Peixiang, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
por: Zhou, Wenping, et al.
Publicado: (2023)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

In vitro evaluation of CAR-T cells in patient-derived glioblastoma models
por: Brakel, Benjamin A., et al.
Publicado: (2021)

Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
por: Si, Xiaohui, et al.
Publicado: (2022)

Hypoxia Enhances Stemness of Cancer Stem Cells in Glioblastoma: An In Vitro Study
por: Li, Pengcheng, et al.
Publicado: (2013)

Visualization of hypoxia in cancer cells from effusions in animals and cancer patients
por: Li, Yue, et al.
Publicado: (2022)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Hypoxia induces connexin 43 dysregulation by modulating matrix metalloproteinases via MAPK signaling
por: Wu, Xianghong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nhgkmp1qne95291ldptuvlisen